Morgan Randall
Interventional Cardiology · Knoxville, TNNPI 1326306523
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (38.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Abbott at 38.9% of the total. Reporting peaked in 2022 at $15,076 and has fallen 51.8% since, to $7,274 in 2025.
Across 195 payments — averaging $148.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$11K
- Medtronic$11K
- Boston Scientific$3K
- Edwards Lifesciences$2K
- Abiomed$339
- Heartflow, Inc.$274
- plus $2K from 21 others
What the payments were for
- Consulting fees$7503%
- Speaking & faculty fees$1,5005%
- Grants$11,16739%
- Travel & lodging$7,43826%
- Food & beverage$7,79827%
- Education$2541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 36 | $11,236 |
| Medtronic(2 entities) | 38 | $10,897 |
| Boston Scientific | 30 | $2,644 |
| Edwards Lifesciences | 18 | $1,650 |
| Abiomed | 4 | $339 |
| Heartflow, Inc. | 5 | $274 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $268 |
| Johnson & Johnson | 3 | $246 |
| Cardiovascular Systems Inc. | 2 | $220 |
| Pfizer | 10 | $171 |
| Philips North America LLC | 1 | $128 |
| Shockwave Medical, Inc | 2 | $110 |
| Inari Medical, Inc. | 1 | $99 |
| Amgen | 5 | $89 |
| Cardiva Medical, Inc. | 5 | $87 |
| Chiesi USA, Inc. | 1 | $79 |
| Inspire Medical Systems, Inc. | 2 | $67 |
| Actelion Pharmaceuticals US, Inc. | 3 | $62 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Sanofi | 1 | $33 |
| Novartis | 2 | $33 |
| AstraZeneca | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Canon Medical Systems USA, Inc. | 1 | $24 |
| Vital Connect, Inc | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Penumbra, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESOLUTE ONYX$9,474
- COROFLOW$4,036
- Ultreon$1,466
- DRAGONFLY OPSTAR$1,375
- Edwards SAPIEN 3 Transcatheter Heart Valve$545
- GENERAL VASCULAR ACCESS$542
- XARELTO$232
- EnSite Precision Cardiac Mapping System$210
- OPTIS$200
- FFRangio$185
- Diamondback Coronary$148
- AVVIGO Guidance System$145
- WATCHMAN Access System$145
- 3F$142
- GENERAL - THERAPIES$142
- GENERAL ATHERECTOMY$139
- SYNERGY$136
- Impella$131
- US Und$128
- FFRct$120
How this compares
$28,907 in reported general payments places this provider in the 80th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 37 | $44,475 |
| EliquisApixaban | 33 | $36,837 |
| EntrestoSacubitril/Valsartan | 34 | $30,672 |
| Prasugrel Hcl | 13 | $1,910 |
| Atorvastatin Calcium | 88 | $670 |
| Metoprolol Succinate | 57 | $651 |
| ClopidogrelClopidogrel Bisulfate | 45 | $498 |
| Rosuvastatin Calcium | 34 | $393 |
| Valsartan | 14 | $242 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 23 | $189 |
| Carvedilol | 37 | $167 |
| Hydrochlorothiazide | 28 | $132 |
| Spironolactone | 19 | $119 |
| Furosemide | 26 | $111 |
| Lisinopril | 12 | $95 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $171 | $36,83733 claims |
| NovartisEntresto | $33 | $30,67234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Knoxville
- Malcolm FosterKnoxville$413K
- Ayaz RahmanKnoxville$251K
- Sara NegrottoKnoxville$114K
- Stuart BreseeKnoxville$112K
- Rachel GoodwinKnoxville$74K
- Joshua ToddKnoxville$45K
- Briana CostelloKnoxville$28K
- Barry MichelsonKnoxville$17K
- Jimmy KerriganNashville$644K
- Kashish GoelNashville$558K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.